Department of Neurological Sciences (Neurology Unit), Milan University, Ospedale Maggiore Policlinico, Milan, Italy.
Curr Vasc Pharmacol. 2010 Jan;8(1):29-34. doi: 10.2174/157016110790226570.
Stroke is a significant cause of long-term disability. Currently, once damage from a stroke is established little can be done to recover lost function. Cell transplantation emerged as possible alternative therapy, on the basis of animal studies showing that cells transplanted into the brain not only survive, but also lead to functional improvement in different neurodegenerative diseases. Stem cells have been tested in stroke patients as a possible treatment option. While initially stem cells seemed to work by a 'cell replacement' mechanism, it is emerging that cell therapy works mostly by providing trophic support to the injured tissue and brain, fostering both neurogenesis and angiogenesis. This review summarizes clinical studies on stem cell transplantation in stroke patients to evaluate the safety, feasibility of administration and tolerability of this experimental treatment. At present there is little evidence to assess the applicability of this treatment in stroke patients and well designed clinical trials are necessary to evaluate safety and toxicity as well as optimal cell type, route and time of delivery.
中风是导致长期残疾的一个重要原因。目前,一旦中风造成的损伤确立,几乎无法恢复失去的功能。细胞移植作为一种可能的替代疗法出现了,其基础是动物研究表明,移植到大脑中的细胞不仅存活下来,而且还导致不同神经退行性疾病的功能改善。干细胞已在中风患者中进行测试,作为一种可能的治疗选择。虽然最初干细胞似乎通过“细胞替代”机制起作用,但现在出现的情况是,细胞疗法主要通过为受损组织和大脑提供营养支持来发挥作用,促进神经发生和血管生成。这篇综述总结了干细胞移植治疗中风患者的临床研究,以评估这种实验性治疗的安全性、给药的可行性和耐受性。目前,几乎没有证据可以评估这种治疗方法在中风患者中的适用性,需要进行精心设计的临床试验来评估安全性和毒性,以及最佳的细胞类型、途径和输送时间。